VaxInnate Corporation
VaxInnate's M2e Universal Influenza Vaccine Candidate Demonstrates Safety and Immunogenicity in Phase I Clinical Study
Published in Vaccine Weekly, September 3rd, 2008
"We'd characterize VaxInnate's M2e universal influenza vaccine candidate as very promising, based upon the immune responses and tolerability we saw in the clinical trial participants," said Christine Turley, MD, Director of clinical trials and clinical research at the Sealy Center for Vaccine Development, University of Texas Medical Branch (UTMB), and the study's primary investigator. "UTMB is committed...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2008-09-03)
More Articles from Vaccine Weekly
- Institute for Operations Research and the Management Sciences
New decision model seeks to avert flu vaccine mismatch of 2007-2008 season - Cytomegalovirus
Research from S. Gorman and co-researchers in the area of cytomegalovirus described - DNA Vaccines
Reports summarize DNA vaccines research from University of Sao Paulo - Foot and Mouth Disease
New foot and mouth disease research reported from S. Choudary and co-authors - Genital Herpesvirus
BioVex Announces Regulatory Clearance to Commence a Clinical Study With ImmunoVEX HSV2; a Vaccine Candidate for Genital Herpes - Immunization
Data from University of Massachusetts provide new insights into immunization - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
